Analgesic and antihyperalgesic effects of dipyrone, meloxicam or a dipyrone–meloxicam combination in bitches undergoing ovariohysterectomy

Zanuzzo, Felipe S.; Neto, Francisco José Teixeira; Teixeira, L. R.; Diniz, Miriely Steim; Souza, V. M.; Thomazini, Camila Martos; Steagall, Paulo V.

doi:10.1016/j.tvjl.2015.05.004

Cited by 23 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the evidence is not as strong in veterinary medicine. Some data regarding clinical and side effects of MT in horses, rabbits, rats, and dogs have been reported, and there is addition data in relation to the pharmacokinetic profile of the metabolite MAA in horses, donkeys, pigs, rats, dogs, cats, and sheep (Aupanun et al., ; Baumgartner et al., ; Burmańczuk et al., ; Christ, Kellner, Ross, Rupp, & Schwarz, ; Flôr, Yazbek, Ida, & Fantoni, ; Giorgi et al., , ; Imagawa et al., ; Klaus, Schlingloff, Kleinitz, Böttcher, & Hapke, ; Lebkowska‐Wieruszewska et al., ; Loescher, ; Roelvink, Goossens, Kalsbeek, & Wensing, ; Silva‐Moreno, Lopez‐Munoz, & Cruz, ; Teixeira et al., ; Zanuzzo et al., ).…”

Section: Discussionmentioning

confidence: 99%

“…MAA and AA are both active metabolites (Vlahov et al, 1990;Weithmann & Alpermann, 1985). In recent years, MT has experienced a revival for pain management in human and veterinary medicine, with pharmacokinetic studies being performed in food-producing animals and pharmacodynamics studies on dogs (Aupanun et al, 2016;Burmańczuk, Kowalski, Giorgi, Owen, & Grabowski, 2016;Giorgi et al, 2015;Giorgi et al, 2017;Imagawa et al, 2011;Kalchofner Guerrero et al, 2015;Schütter, Tünsmeyer, & Kästner, 2016;Teixeira et al, 2013;Zanuzzo et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

“…The panel focus on the relevant area of the curve where the IC50s (-) for the human COX enzymes are located F I G U R E 4 Mean plasma concentrations of 4-aminoantypyrine (AA) vs. time curves following intravenous ( ), intramuscular ( ), oral ( ), and rectal ( ) dose of 25 mg⁄kg metamizole (MT) in healthy dogs (n = 6). Bars represent the standard deviations ,& Schwarz, 1973;Flôr, Yazbek, Ida, & Fantoni, 2013;Giorgi et al, 2015Giorgi et al, , 2017Imagawa et al, 2011;Klaus, Schlingloff, Kleinitz, Böttcher, & Hapke, 1997;Lebkowska-Wieruszewska et al, 2017;Loescher, 1993;Roelvink, Goossens, Kalsbeek, & Wensing, 1991;Silva-Moreno, Lopez-Munoz, & Cruz, 2009;Teixeira et al, 2013;Zanuzzo et al, 2015).Due to MT's striking pharmacological effect, low cost and safety profile, there has been growing interest in its use in the veterinary field over the past decade. Although MT is widely used in clinical practice, pharmacokinetic-pharmacodynamic profiles of MT or its active metabolites are limited or absent.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Pharmacokinetic profiles of the active metamizole metabolites after four different routes of administration in healthy dogs

Giorgi

Łebkowska‐Wieruszewska

Lisowski

et al. 2018

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Metamizole (MT), an analgesic and antipyretic drug, is rapidly hydrolyzed to the active primary metabolite 4-methylaminoantipyrine (MAA) and relatively active secondary metabolite 4-aminoantipyrine (AA). The aim of this study was to assess the pharmacokinetic profiles of MAA and AA after dose of 25 mg/kg MT by intravenous (i.v.), intramuscular (i.m.), oral (p.o.), and rectal (RC) routes in dogs. Six dogs were randomly allocated to an open, single-dose, four-treatment, four-phase, unpaired, crossover study design. Blood was collected at predetermined times within 24 hr, and plasma was analyzed by a validated HPLC-UV method. Plasma concentrations of MAA and AA after i.v., i.m., p.o., and RC administrations of MT were detectable from 5 (i.v. and i.m.) or 30 (p.o. and RC) min to 24 hr in all dogs. The highest concentrations of MAA were found in the i.v., then i.m., p.o., and RC groups. Plasma concentrations of AA were similar for i.v., i.m., and RC, and the concentrations were approximately double those in the PO groups. The AUC ratio for MAA was 0.75 ± 0.11, 0.59 ± 0.08, and 0.32 ± 0.05, for i.m., p.o., and RC, respectively. The AUC ratio for AA was 1.21 ± 0.33, 2.17 ± 0.62, and 1.08 ± 0.19, for i.m., p.o., and RC, respectively. Although further studies are needed, rectal administration seems to be the least suitable route of administration for MT in the dog.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Pharmacokinetic profiles of the active metamizole metabolites after four different routes of administration in healthy dogs

Giorgi

Łebkowska‐Wieruszewska

Lisowski

et al. 2018

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…In veterinary medicine however, the scenario is totally different as the evidence from veterinary studies is not as strong as that from the human literature. There are some data available concerning clinical and side effects of MT in horses (Roelvink et al, 1991), rabbits (Baumgartner et al, 2009), rats (Silva-Moreno et al, 2009) and dogs (Imagawa et al, 2011;Flôr et al, 2013;Teixeira et al, 2013;Zanuzzo et al, 2015) and some concerning the pharmacokinetic profile of its metabolite MAA in horses (Klaus et al, 1997), rats, and dogs (Christ et al, 1973) and sheep (Giorgi et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic profiles of the active metamizole metabolites in healthy horses

Giorgi

Aupanun

Lee

et al. 2016

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Metamizole (MT) is an analgesic and antipyretic drug labelled for use in humans, horses, cattle, swine and dogs. MT is rapidly hydrolysed to the active primary metabolite 4-methylaminoantipyrine (MAA). MAA is formed in much larger amounts compared with other minor metabolites. Among the other secondary metabolites, 4-aminoantipyrine (AA) is also relatively active. The aim of this research was to evaluate the pharmacokinetic profiles of MAA and AA after dose of 25 mg/kg MT by intravenous (i.v.) and intramuscular (i.m.) routes in healthy horses. Six horses were randomly allocated to two equally sized treatment groups according to a 2 × 2 crossover study design. Blood was collected at predetermined times within 24 h, and plasma was analysed by a validated HPLC-UV method. No behavioural changes or alterations in health parameters were observed in the i.v. or i.m. groups of animals during or after (up to 7 days) drug administration. Plasma concentrations of MAA after i.v. and i.m. administrations of MT were detectable from 5 min to 10 h in all the horses. Plasma concentrations of AA were detectable in the same range of time, but in smaller amounts. Maximum concentration (C ), time to maximum concentration (T ) and AUMC of MAA were statistically different between the i.v. and i.m. groups. The AUC /AUC ratio of MAA was 1.06. In contrast, AUC of AA was statistically different between the groups (P < 0.05) with an AUC /AUC ratio of 0.54. This study suggested that the differences in the MAA and AA plasma concentrations found after i.m. and i.v. administrations of MT might have minor consequences on the pharmacodynamics of the drug.

show abstract

“…There are also many studies that support the analgesic benefit of administering a NSAID for acute pain relief after different types of surgery in dogs (Gruet and others 2011, 2013, Delgado and others 2014, Zanuzzo and others 2015) and cats (Kamata and others 2012, Polson and others 2012, Speranza and others 2015). However, NSAIDs are not without side effects (Lascelles and others 2005, Monteiro-Steagall and others 2013, Hunt and others 2015a) and, although some risk factors for adverse events have been identified, it remains difficult to identify in advance, which individual patient may develop side effects as a result of perioperative NSAID administration.…”

mentioning

confidence: 99%

Perioperative use of non‐steroidal anti‐inflammatory drugs in cats and dogs

Murrell¹

2018

In Practice

View full text Add to dashboard Cite

Non-steroidal anti-inflammatory drugs (NSAIDs) are efficacious analgesics that contribute to preventive and multimodal analgesic techniques. They are widely used for routine surgeries in cats and dogs and there is some evidence that it is advantageous to give NSAIDs before the start of surgery, rather than in the postoperative period. Despite their efficacy, the side effects of NSAIDs should always be taken into consideration when deciding whether to administer them to a particular patient. The kidney is a particularly vulnerable organ during anaesthesia, due to the high prevalence of hypotension in anaesthetised patients; the administration of a NSAID preoperatively means that it is imperative to monitor and support blood pressure during anaesthesia to prevent renal compromise on recovery. This article summarises the mechanism of action of NSAIDs and provides guidance for practitioners on their use in the perioperative period.

show abstract

Analgesic and antihyperalgesic effects of dipyrone, meloxicam or a dipyrone–meloxicam combination in bitches undergoing ovariohysterectomy

Cited by 23 publications

References 20 publications

Pharmacokinetic profiles of the active metamizole metabolites after four different routes of administration in healthy dogs

Pharmacokinetic profiles of the active metamizole metabolites after four different routes of administration in healthy dogs

Pharmacokinetic profiles of the active metamizole metabolites in healthy horses

Perioperative use of non‐steroidal anti‐inflammatory drugs in cats and dogs

Contact Info

Product

Resources

About